Dr. Robert E. Springer, M.D.
Internal Medicine (Internal Medicine Physician)
Medicare and federal program status
Opted out of Medicare from April 1, 2016 through April 1, 2028. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly. They can still order tests and refer Medicare patients to other providers.
Source: CMS Medicare Opt Out Affidavits (record last updated April 16, 2026). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
GA license 037081
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Alprazolam Other prescribers in Atlanta, GA | 131 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Atlanta, GA | 112 |
| Oxycodone Hcl Other prescribers in Atlanta, GA | 110 |
| Zolpidem Tartrate Other prescribers in Atlanta, GA | 106 |
| Gabapentin Other prescribers in Atlanta, GA | 57 |
| Mounjaro (tirzepatide) Other prescribers in Atlanta, GA | 55 |
| Levothyroxine Sodium Other prescribers in Atlanta, GA | 54 |
| Trazodone Hcl Other prescribers in Atlanta, GA | 49 |
| Doxycycline Hyclate Other prescribers in Atlanta, GA | 49 |
| Tizanidine Hcl Other prescribers in Atlanta, GA | 46 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 29 payments worth $485 in total to this clinician.
| AbbVie Inc. | $146 |
|---|---|
| Astellas Pharma US Inc | $100 |
| Exact Sciences Corporation | $56.47 |
| Takeda Pharmaceuticals U.S.A., Inc. | $48.43 |
| Ionis Pharmaceuticals, Inc. | $36.28 |
| Almatica Pharma LLC | $34.03 |
| Lilly USA, LLC | $33.58 |
| Pfizer Inc. | $30.02 |
| Food and Beverage | $485 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $1,688,781 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
ModernaTX, Inc. · Completed · NCT07089706 - A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
ModernaTX, Inc. · Completed · NCT05815498 - A phase 3 randomized doubleblind placebocontrolled clinical study evaluating the safety tolerability immunogenicity and efficacy of a variantadapted BNT162B2 vaccine in healthy participants 50 through 64 years of age
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.